![Michael Cannon](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Cannon
Director/Board Member at
MOLECULIN BIOTECH, INC.
Net worth: - $ as of 2026-08-30
Profile
Michael D.
Cannon is currently Director at Osel, Inc. and Eureka Therapeutics, Inc. He is Independent Director at Moleculin Biotech, Inc. since 2015 and Executive Director at Biosentinel, Inc. since 2010.
Former roles include Director, Chief Science Officer & Executive VP at SICOR, Inc. from 1997 to 2004.
Other former positions include Director at Metabasis Therapeutics, Inc., Independent Director at Athenex, Inc., Director at Waterstone Pharmaceuticals, Inc., Director at Antiva Biosciences, Inc., and Strategic Partner at Trevi Management LP.
Education includes undergraduate studies at Fordham University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-08-18 | 0 ( -.--% ) | - $ | 2026-08-30 |
Michael Cannon active positions
| Companies | Position | Start |
|---|---|---|
| MOLECULIN BIOTECH, INC. | Director/Board Member | 2015-06-30 |
Eureka Therapeutics, Inc.
 Eureka Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops T-cell therapies for cancer patients with solid tumors | Director/Board Member | - |
Osel, Inc.
 Osel, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes live biotherapeutic products that prevent abnormal conditions resulting from a disruption of the human microbiome | Director/Board Member | - |
Biosentinel, Inc.
 Biosentinel, Inc. BiotechnologyHealth Technology Develops tests for the detection of the botulinum neurotoxins | Director/Board Member | 2010-06-30 |
Former positions of Michael Cannon
| Companies | Position | End |
|---|---|---|
SICOR, Inc.
 SICOR, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Chief Tech/Sci/R&D Officer | 2003-12-31 |
| ATHENEXPAR | Director/Board Member | - |
Antiva Biosciences, Inc.
 Antiva Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops antiviral therapeutics | Director/Board Member | - |
Metabasis Therapeutics, Inc.
 Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops small molecule drugs | Director/Board Member | - |
Waterstone Pharmaceuticals, Inc.
 Waterstone Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in activities ranging from drug discovery of proprietary new chemical entities, custom development and manufacturing services, and generic drug development and manufacturing | Director/Board Member | - |
Training of Michael Cannon
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
35
1st degree connections
11
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 11 |
|---|---|
SICOR, Inc.
SICOR, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Health Technology |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops small molecule drugs | Health Technology |
Athenex, Inc.
 Athenex, Inc. BiotechnologyHealth Technology Develops and commercializes drugs for cancer and immunomodulatory diseases | Health Technology |
Osel, Inc.
Osel, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes live biotherapeutic products that prevent abnormal conditions resulting from a disruption of the human microbiome | Health Technology |
Eureka Therapeutics, Inc.
Eureka Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops T-cell therapies for cancer patients with solid tumors | Health Technology |
Waterstone Pharmaceuticals, Inc.
Waterstone Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in activities ranging from drug discovery of proprietary new chemical entities, custom development and manufacturing services, and generic drug development and manufacturing | Health Technology |
Antiva Biosciences, Inc.
Antiva Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops antiviral therapeutics | Health Technology |
Fordham University
 Fordham University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Trevi Management LP
 Trevi Management LP Investment ManagersFinance Trevi Health Capital seeks investment opportunities in middle market companies across the globe. The firm focuses on healthcare sectors such as healthcare information technology, healthcare services, and medical technology. It participates in growth stages, traditional buyouts, special situations, and structured finance transactions with an investment size of at least USD 500 million. It also acts as a lead or co-lead investor. | Finance |
Moleculin Biotech, Inc.
 Moleculin Biotech, Inc. Pharmaceuticals: MajorHealth Technology Engages in the development of treatments for highly resistant cancers and viruses | Health Technology |
Biosentinel, Inc.
Biosentinel, Inc. BiotechnologyHealth Technology Develops tests for the detection of the botulinum neurotoxins | Health Technology |
- Stock Market
- Insiders
- Michael Cannon
